Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia
- Conditions
- Leukemia
- Interventions
- Genetic: microarray analysisGenetic: polymerase chain reaction
- Registration Number
- NCT00897182
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Brief Summary
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify genes related to cancer. It may also help doctors diagnose cancer and predict how patients will respond to treatment.
PURPOSE: This research study is identifying cancer-related genes in blood and/or bone marrow samples from patients with acute myeloid leukemia.
- Detailed Description
OBJECTIVES:
* To identify and validate individual genes for diagnosis of three major translocations in acute myeloid leukemia.
* To correlate transcript expression data in the various translocations with age, sex, race, response to treatment, and survival and with other known mutations.
OUTLINE: Blood and/or bone marrow samples previously procured from patients on CALGB-9665 are obtained from the CALGB Leukemia Tissue Bank from patients enrolled on CALGB AML treatment studies. Mononuclear cells are isolated from samples and mRNA is extracted. Gene expression profiles are analyzed via custom mRNA microarray and confirmed by quantitative real-time PCR.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 96
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group 1 polymerase chain reaction This is a CALGB Leukemia Tissue Bank project makes use of tissue from patients who have previously provided their consent. Diagnostic samples from patients enrolled on CALGB AML treatment studies (eg, CALGB 9621, 9710, and 19808) and who have been registered on the companion Leukemia Tissue Bank Protocol CALGB 9665 were used. Group 1 microarray analysis This is a CALGB Leukemia Tissue Bank project makes use of tissue from patients who have previously provided their consent. Diagnostic samples from patients enrolled on CALGB AML treatment studies (eg, CALGB 9621, 9710, and 19808) and who have been registered on the companion Leukemia Tissue Bank Protocol CALGB 9665 were used.
- Primary Outcome Measures
Name Time Method Correlation of increased or decreased expression of same transcripts with disease outcome baseline Minimum number of genes that can be used for precise diagnosis of each of the three subtypes of acute myeloid leukemia baseline Identification of individual genes that are differentially expressed between the subtypes of AMLs baseline Correlation of the patterns of expression of the translocation-specific transcripts with age, sex, race, response to treatment, survival, and with other known mutations baseline
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Fort Wayne Medical Oncology and Hematology
🇺🇸Fort Wayne, Indiana, United States
Wayne Memorial Hospital, Incorporated
🇺🇸Goldsboro, North Carolina, United States